By Aneesh Garg, DO, CAQ · Double Board-Certified Sports Medicine Physician · Medical Director, American Shockwave Training Institute · Team Physician, USA Hockey and U.S. Soccer
Choosing MFAT or BMA, Never Both: A Higher Standard of Regenerative Orthobiologics
At Dynamic Athlete, we practice regenerative orthobiologics with precision built specifically for Boulder’s active adults.
We select ONE biologic (MFAT or BMA) based on tissue biology, imaging, biomechanics, and movement demands. We never combine them.
This clarity creates predictable, long-term outcomes.
In Boulder and across Colorado, “stem cell therapy” is often marketed inaccurately.
We differentiate ourselves by using modern orthobiologic science: MFAT for joint structure, BMA for tendon signaling.
We never mix biologics, never overprocess tissue, and perform 100% ultrasound‑guided injections.
In orthopedic regenerative medicine, the cells used are your own. They are harvested, concentrated at the point of care, and returned to the injured tissue during the same appointment. The most accurate name for them is mesenchymal signaling cells (MSCs): autologous, minimally manipulated cells that release anti-inflammatory and signaling proteins.
Precision in language matters here, because the field is crowded with marketing. This treatment does not use embryonic cells. It is not an off-the-shelf amniotic, placental, or umbilical cord product sold from a vial. It does not rebuild a joint on command, and no honest clinic can promise a specific outcome. What it can do, for the right patient, is improve the local healing environment and reduce pain and dysfunction. That is a meaningful goal, and it is an honest one.
The older idea was that injected cells become new cartilage or tendon directly. The current understanding is more accurate: MSCs work mostly by signaling. They release growth factors and cytokines that modulate inflammation, recruit your body’s own repair cells, and improve tissue turnover at the site. In other words, they change the environment so your own biology can heal more effectively. This is why patient selection and precise placement matter more than raw cell count, and why the treatment is a planned procedure rather than a commodity injection.
MFAT (Microfragmented Fat) is chosen when a joint requires structural, cushioning, or inflammatory-environment support. At Dynamic Athlete, MFAT is never chosen because it is “popular.” It is selected because it is the biologically correct treatment for specific patterns of joint deterioration, cartilage thinning, synovial inflammation, and chronic stiffness that interfere with higher-level movement.
MFAT provides a microarchitectural scaffold capable of supporting joint mechanics in ways that other biologics cannot. Unlike BMA, which is designed primarily for signaling and soft‑tissue regeneration, MFAT directly influences the joint environment itself. This makes it ideal for active adults experiencing early arthritic changes, post‑traumatic cartilage wear, or chronic synovial irritation.
A joint cannot operate efficiently if the cartilage surface is breaking down or the synovial lining is inflamed. Boulder’s athletes feel this acutely, whether running downhill, squatting heavy, or hiking steep inclines. MFAT supports smoother joint mechanics and reduces cytokine-driven irritation so athletes can move the way they’re built to move.
Patients typically notice:
MFAT supports long-term comfort and performance when cartilage or joint environment issues are the primary drivers of pain. It is not interchangeable with BMA, and this distinction is why our biologic outcomes remain consistent and aligned with each patient’s athletic goals.
There is no single cell source that is correct for every condition. Bone marrow and adipose tissue behave differently, and matching the source to the pathology is one of the decisions that most influences the result.
| Biologic source | Where it comes from | Biology and typical use |
|---|---|---|
| Bone Marrow Aspirate (BMA) | Drawn from the iliac crest of your pelvis, then concentrated to raise cell yield | Rich in signaling cells and growth factors that drive repair; a well-studied autologous option for bone, cartilage, and joint pathology |
| Micro-Fragmented Adipose Tissue (MFAT) | Harvested from your own fat by minimally invasive aspiration, then mechanically fragmented, not enzymatically expanded | A dense source of signaling cells and stromal vascular fraction that supports the joint environment; suited to joint, soft-tissue, and select tendon problems |
Neither is universally superior. Bone marrow is often chosen where the driver is bone, cartilage, or signaling; adipose is often chosen where the joint environment and structural support are the priority. The selection is a clinical judgment made after imaging, not a patient menu choice, and it is why a serious practice offers both.
BMA contains bioactive components that influence tendon healing, collagen turnover, and enthesis repair. It is NOT chosen for joint space cushioning. It is chosen for its ability to restart a stalled healing response in tissues that have fatigued, weakened, or degenerated over time.
BMA is highly effective for runners, climbers, cyclists, and heavy lifters experiencing:
BMA does not provide structural cushioning. It does not stabilize synovitis. It does not reduce joint compression symptoms. When joint deterioration is the primary issue, MFAT is the superior biologic.
Patients typically notice:
BMA is the correct choice for biologic signaling, tendon remodeling, and enthesis regeneration. At Dynamic Athlete, we make this distinction deliberately, choosing BMA only when the biology and biomechanics of the injury demand it.
Being honest about candidacy is the foundation of good regenerative care, and the patients who are told no matter as much as the ones who are treated. Stem cell therapy tends to fit active adults with degenerative or partial-tissue injury who want a non-surgical option and hold realistic expectations. It is generally not the right tool for a complete structural tear that needs surgical repair, for advanced bone-on-bone arthritis better served by other options, or for anyone with an active infection or certain cancers. A physician consultation and an imaging review are required to determine whether it fits your specific case.
At Dynamic Athlete, one of our strongest clinical principles is this: we never combine MFAT and BMA in the same procedure. This is not a marketing stance or a preference. It is grounded in biologic logic, scientific clarity, and the outcomes we deliver to Boulder’s active adult population.
Other clinics often claim that combining multiple biologics creates a “super treatment,” but the emerging evidence, combined with decades of regenerative biomechanics, shows the opposite: stacking MFAT and BMA frequently leads to biologic confusion, reduced clarity of effect, and unnecessary cost. Our method is built around precision, not excess.
These tissues have fundamentally different roles. Mixing them blurs the intended purpose.
There is no high‑quality research showing better outcomes when MFAT and BMA are combined. Most claims come from marketing, not biologic science.
3. Layering Biologics Increases Cost Without Increasing Benefit
Many clinics combine biologics to justify a higher-priced procedure. This is not patient‑centered care. We focus on the right biologic, not the most expensive one.
4. Combined Biologics Decrease Diagnostic Clarity
When two biologics are used, it becomes impossible to determine which one produced the outcome. This reduces the ability to refine future care and personalize treatment.
5. Mixing Tissues May Dilute Each Biologic’s Strength
MFAT has a specific structural role in joint mechanics; BMA has a specific biological signaling role for tendon healing. Mixing them can dilute the purity of each biologic’s effect.
6. Competitors Use Combination Procedures as a Sales Strategy
This is one of the most common red flags in Colorado’s orthobiologic market.
At Dynamic Athlete, we never mix biologics to inflate price or create the illusion of a more powerful treatment.
This clarity is one of the reasons our regenerative outcomes remain consistent, logical, and high‑performing across Boulder’s running, climbing, cycling, skiing, and lifting communities.
MFAT and BMA each play powerful, but very different, roles.
The skill is knowing which biologic belongs with which injury, not combining them and hoping for the best.
Platelet-Rich Plasma (PRP) plays a strategic, supportive role in our orthobiologic framework. At Dynamic Athlete, PRP is not automatically bundled with MFAT or BMA without thought. Instead, we use PRP when its biology aligns with the specific tissue-level needs of the patient. This selective, evidence-driven approach is one of the key differences between our clinic and others who treat PRP as a default add-on rather than a targeted biologic amplifier.
PRP is a concentration of a patient’s own platelets and growth factors, prepared through a gentle centrifugation process. When used correctly, PRP enhances healing by improving cellular signaling, supporting collagen maturation, and stabilizing biologic effects. When used incorrectly, it adds cost without contributing meaningful therapeutic benefit.
PRP does not replace MFAT or BMA.
PRP does not increase the potency of a biologic that is already correctly selected.
PRP only provides value when the targeted tissue needs enhanced growth factor support to accelerate or reinforce healing.
PRP may be used with MFAT in cases involving:
PRP helps stabilize the joint’s inflammatory behavior and improves the synovial lining’s response to MFAT.
PRP may be used with BMA when treating:
PRP helps stimulate growth factor pathways that enhance tendon remodeling and support BMA-driven biologic signaling.
We do NOT use PRP when:
The purpose of PRP is to assist, not replace or overshadow, MFAT or BMA.
By treating PRP as a precise tool rather than a universal add-on, we improve outcomes and ensure that each biologic serves its intended role. This attention to detail is why Boulder’s active adults trust Dynamic Athlete for high-level regenerative care.
At Dynamic Athlete, choosing between MFAT and BMA is never guesswork. It is a structured, medically precise, movement-informed diagnostic process that reflects the complexity of Boulder’s active adult population. Most biologic failures occur not because the biologic was weak, but because the biologic did not match the injury. Our diagnostic model prevents that mismatch.
We evaluate the entire ecosystem: tissue biology, imaging, biomechanics, and load tolerance. We do this before recommending MFAT or BMA. This is the foundation of our biologic practice.
The result: the right biologic for the right tissue, every time.
Ultrasound allows real-time visualization of:
Unlike MRI, ultrasound lets us analyze tissues during movement, contraction, and stress. It reveals whether joint structure (MFAT) or tendon/enthesis biology (BMA) is the primary problem.
BMA is chosen when:
This distinction is essential. Treating tendon problems with joint biologics, or vice versa, produces poor outcomes.
Movement patterns clarify whether the issue is structural (MFAT) or tissue‑based (BMA).
Each sport produces a different biologic footprint. MFAT or BMA must match that footprint.
We identify:
These clues point directly toward a joint‑dominant or tendon‑dominant source.
Other clinics choose biologics based on marketing or habit.
We choose based on:
This diagnostic map allows us to select MFAT or BMA with confidence, precision, and consistency, resulting in better outcomes for athletes who cannot afford guesswork.
Dynamic Athlete treats a spectrum of joint and tendon conditions using MFAT or BMA, never both. Each biologic is selected based on the exact tissue involved, the structural demands of the patient’s sport, and the findings from ultrasound, biomechanics, and load testing. Boulder’s active population presents a unique distribution of injuries, and our biologic decision-making reflects the real athletic patterns we see every day.
Below is a clear breakdown of which conditions are best treated with MFAT, and which are best treated with BMA. This distinction is central to our practice and one of the main reasons our orthobiologic outcomes outperform regional clinics.
MFAT is selected when the structural elements of the joint are the limiting factor. These cases often present with cartilage damage, synovial inflammation, and load‑related stiffness.
MFAT addresses the joint environment itself, improving cushioning, inflammatory regulation, and mechanical surface behavior.
BMA is the superior biologic for tendon, ligament, and enthesis degeneration, especially when the tissue has lost its ability to remodel under normal training conditions.
Joint problems treated with tendon biologics fail.
Tendon problems treated with joint biologics fail.
The key to regenerative success is matching the biologic to the biology.
This separation is rare among orthobiologic clinics, and it remains one of our strongest competitive advantages.
At Dynamic Athlete, the MFAT or BMA procedure is performed with a level of precision designed specifically for active adults who rely on durable, high-performing tissue. Every step, from evaluation to harvest to reintegration, is engineered to match the biology of the injured structure and the biomechanical demands of each patient’s sport. This is not a generic “stem cell” procedure. It is a targeted orthobiologic intervention performed with medical rigor.
Your procedure begins long before the biologic is harvested. We perform:
This evaluation determines whether MFAT or BMA is the correct biologic.
No biologic decision is made until imaging and biomechanics align.
We mark precise harvest sites using ultrasound:
We avoid guesswork. This planning ensures that the biologic begins with the highest-quality source material possible.
Most patients describe the harvest as pressure with brief moments of intensity, but entirely tolerable.
Our harvest technique directly affects your outcome.
We treat source tissue with respect because biologics must retain their structure and viability.
We avoid aggressive centrifugation or excessive manipulation.
Our processing principles:
This is where many clinics fail.
We treat the biologic like a living material, not a commodity.
All injections are performed under live ultrasound guidance:
The biologic is delivered exactly where it is needed, never “near” the injury.
We guide patients through:
This protects the biologic during its early integration phase.
Once the biologic is integrated, we begin load reintegration:
The speed of progress depends on:
We build a structured return-to-sport roadmap:
Our biomechanical team ensures the biologic succeeds long-term, not just on paper.
This entire process is why MFAT and BMA succeed at Dynamic Athlete while they often fail elsewhere.
Precision harvesting, gentle processing, targeted injection, and post-procedure biomechanics are not “extras.” They are the foundation of successful regenerative medicine.
Regenerative orthobiologics deliver change gradually, predictably, and in alignment with tissue biology. At Dynamic Athlete, we set clear expectations for MFAT and BMA because each biologic follows its own timeline. Boulder’s active adults often push hard, recover quickly, and expect rapid results, but true biologic regeneration follows a structured pace that reflects how cartilage, tendon, and enthesis respond to load, inflammation, and metabolic signaling.
Below is a comprehensive timeline of what athletes typically experience with MFAT or BMA. These ranges represent thousands of clinical encounters and reflect the biology of tissue healing, not marketing promises.
MFAT is not an overnight solution. It is structural support that improves the environment of the joint over time.
BMA reactivates stalled healing in tendon, ligament, and enthesis tissue. Unlike MFAT, which affects cushioning, BMA affects biology at the cellular and fiber level.
BMA’s benefits accumulate through structured mechanical loading. This is why our regenerative loading progression is essential.
Neither MFAT nor BMA works in isolation.
The biologic provides the foundation.
Movement delivers the adaptation.
At Dynamic Athlete, we guide patients through:
This is why our outcomes are consistently stronger than clinics that rely on biologics alone.
Patients who combine Dynamic Stem Cell+ with Dynamic Mind+ (ExoMind neurostimulation) often report improved sleep, lower stress, and better compliance with their regenerative loading plan. For athletes with concurrent core or pelvic floor instability, Dynamic Core+ (EMSELLA) restores the deep stabilizers that protect healing tissue during return-to-sport progression.
Patients consistently report:
Most importantly, biologics allow Boulder athletes to continue doing what they love without being limited by chronic joint or tendon issues.
Across PRP, Stem Cell, Shockwave, EXOMIND, and EMSELLA. Tracked across active adults, postpartum patients, athletes, and surgery-avoiders.
We have answered the most common questions about Dynamic Stem Cell+, including how we decide between MFAT and BMA, why we never combine both, what recovery looks like for active adults, how stem cell therapy compares to surgery, and what patients experience at each stage of healing. Our complete FAQ covers 53 questions with the clinical depth and real outcomes you need to make an informed decision.
All Dynamic PRP+ and Dynamic Stem Cell+ procedures are performed exclusively by Dr. Garg. Dynamic Shockwave+, Dynamic Mind+, and Dynamic Core+ are performed by Dr. Garg and his clinical team.
Aneesh Garg, DO, CAQ. Founder of Dynamic Athlete Sports Medicine and Regenerative Orthopaedics. Yale residency trained. Andrews Sports Medicine fellowship trained. Double board-certified Sports Medicine and Internal Medicine. Team Physician USA Hockey and U.S. Soccer. Founder and Medical Director of ASTI (American Shockwave Training Institute).
Teaching faculty RMTI and Rocky Vista University. Host of The Regen Doc podcast. Dr. Garg developed the Dynamic PRP+, Dynamic Stem Cell+, Dynamic Shockwave+, Dynamic Mind+, and Dynamic Core+ protocols used at this practice.
Yale residency trained. Andrews Sports Medicine fellowship trained. Double board-certified Sports Medicine and Internal Medicine.
Yale-New Haven Hospital residency
Fellowship-trained at the American Sports Medicine Institute (ASMI) / Andrews Sports Medicine
Team Physician for USA Hockey and U.S. Soccer
Medical Director of the American Shockwave Training Institute (ASTI), training clinicians nationwide in ESWT, RPW, and EMTT
Known for physician-performed, ultrasound-guided PRP, BMA/MFAT, and shockwave-primed biologic injections
The Regen Doc breaks down real patient cases, protocol design, and what actually works vs. what the industry sells. New episodes on Apple Podcasts, Spotify, and wherever you get your podcasts.
Talk with our team about whether you're a candidate. Care is directed by Aneesh Garg, DO, CAQ, here in Boulder.
Request a consult No obligation. We'll help you understand your options.